| Description | Paritaprevir (ABT450) is an inhibitor of non-structural protein 3/4A protease with EC50 values of 1 and 0.21 nM for HCV 1a and HCV 1b, respectively. |
| In vivo | Paritaprevir/ritonavir/ombitasvir与dasabuvir（PrOD）是一种新型组合化合物，包含由ritonavir增效的非结构性(NS) 3/4A蛋白抑制剂、一个NS5A蛋白抑制剂以及一个NS5B非核苷类聚合酶抑制剂。paritaprevir、ritonavir、ombitasvir（NS5A蛋白抑制剂）和dasabuvir（NS5B非核苷聚合酶抑制剂）的组合，无论是否加用RBV，均已获批用于治疗HCV基因型1感染1[1]。 |
| Target activity | HCV NS3/4A 4a:0.09 nM, HCV NS3/4A 6a:0.69nM, HCV NS3/4A 1a:1.0 nM, HCV NS3/4A 2a:5.3 nM, HCV 1a:1 nM(EC50), HCV NS3/4A 1b:0.21 nM, HCV NS3/4A 3a:19 nM, HCV 1b:0.21 nM(EC50) |
| Synonyms | ABT450, ABT-450, 帕利普韦, Veruprevir |
| molecular weight | 765.88 |
| Molecular formula | C40H43N7O7S |
| CAS | 1216941-48-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 80 mg/mL (104.46 mM) |
| References | 1. Deeks ED. Drugs. 2015, 75(9):1027-38. 2. Pilot-Matias T, et al. Antimicrob Agents Chemother. 2015, 59(2):988-97. |